Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 42.189
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2631
- MktCap 701390981520.0
- FreeCF/Share 0.5421
- PFCF 1439.6367
- PE 59.8845
- Debt/Assets 0.4309
- DivYield 0.0076
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Published: April 23, 2025 by: The Motley Fool
Sentiment: Neutral
Eli Lilly (LLY 0.73%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023.
Read More
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects. However, you don't necessarily have to sacrifice growth for safety.
Read More
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Published: April 22, 2025 by: WSJ
Sentiment: Negative
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
Read More
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
Read More
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.
Read More
Strength Seen in Lilly (LLY): Can Its 14.3% Jump Turn into More Strength?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Published: April 21, 2025 by: The Motley Fool
Sentiment: Positive
Novo Nordisk (NVO -7.78%) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss -- but doctors have prescribed either for weight management.
Read More
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing
Published: April 18, 2025 by: Barrons
Sentiment: Positive
Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.
Read More
Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What's Driving Markets Thursday?
Published: April 17, 2025 by: Benzinga
Sentiment: Positive
Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled positive momentum in trade negotiations.
Read More
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
Published: April 17, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages over competitors including easier manufacturing, no liver safety signals, and simpler administration than Novo Nordisk's option. Lilly reported $13.5B Q4 revenue (+32% YoY), driven by Mounjaro and Zepbound, with 2025 guidance of $58-61B.
Read More
Top Stock Movers Now: UnitedHealth, Nvidia, Eli Lilly and More
Published: April 17, 2025 by: Investopedia
Sentiment: Negative
The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points as UnitedHealth Group (UNH) shares plunged. The tech-heavy Nasdaq and the S&P 500 were slightly higher.
Read More
Here's Why Eli Lilly (NYSE: LLY). Fidelity National (NYSE: FIS) and Diamondback Energy (Nasdaq: FANG) Are Soaring Today
Published: April 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
The Dow Jones Industrial Average is tumbling by another 440 points in midday trading today, as President Trump criticized Federal Reserve chairman Jerome Powell's position, but the fact he is not trying to fire him heartened enough investors that the S&P 500 has bounced back into positive territory.
Read More
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Published: April 17, 2025 by: The Motley Fool
Sentiment: Positive
It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (LLY 15.96%) stock is off to the races!
Read More
Lilly confirms date and conference call for first-quarter 2025 financial results announcement
Published: April 17, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Read More
S&P500 and Dow Jones: UnitedHealth Drops 19%, Eli Lilly Jumps on Trial Results
Published: April 17, 2025 by: FXEmpire
Sentiment: Neutral
S&P and Nasdaq futures rebound while Dow lags as UnitedHealth sinks 19% on earnings miss; Eli Lilly and Hertz post big premarket gains.
Read More
Eli Lilly shares surge on strong trial results for weight-loss pill
Published: April 17, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) shares jumped 12% in premarket trading on Thursday after the drugmaker said its experimental weight-loss pill, orforglipron, succeeded in a late-stage trial in patients with type 2 diabetes, showing promise as a potential rival to injectable treatments like Ozempic. The once-daily oral drug significantly reduced blood sugar levels and body weight in the Phase 3 trial, marking a milestone as the first oral GLP-1 receptor agonist to reach this stage without requiring food or water restrictions.
Read More
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics
Published: April 17, 2025 by: Business Wire
Sentiment: Neutral
SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences (“BigHat”), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, announced a strategic collaboration with Eli Lilly and Company (“Lilly”). In this collaboration, BigHat will deploy its Milliner platform, a suite of state-of-the-art ML technologies integrated with a synthetic biology-based high-speed wet lab, to design and engineer therapeutic antibodies with superior functionality. BigHat.
Read More
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
Published: April 16, 2025 by: Seeking Alpha
Sentiment: Positive
VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV's pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly.
Read More
European pharma companies issue demands to stay in EU ahead of expected US tariffs
Published: April 15, 2025 by: Reuters
Sentiment: Negative
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations, French business newspaper Les Echos reported on Tuesday.
Read More
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Published: April 14, 2025 by: The Motley Fool
Sentiment: Positive
Bad news for Pfizer (PFE 1.07%) turned into good news for Eli Lilly (LLY 2.42%), Novo Nordisk (NVO 2.23%), and Viking Therapeutics (VKTX 8.48%) Monday morning, each of which is rising on Pfizer's latest product announcement.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Published: April 09, 2025 by: The Motley Fool
Sentiment: Negative
Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of the stock market. On Wednesday, Reuters reported that President Donald Trump is preparing to unveil a new series of tariffs on pharmaceutical imports.
Read More
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000